鼎源醫藥OncoLattice Bio / AAI Inc.

洞察

早期腫瘤開發中,哪些訊號值得先看?

這裡整理公開研究、腫瘤會議訊號和我們對 FIH 執行風險的觀點。Apex AI 公開研究索引和 ASCO、ESMO、AACR、SITC 等官方來源會作為可篩選的資訊補充,所有卡片保留原始公開連結。

公開資訊庫

公開研究與腫瘤會議訊號

把 Apex AI 公開研究索引和 ASCO、ESMO、AACR、SITC 等官方公開來源放在同一個列表裡。可按來源、主題和關鍵詞篩選;所有卡片只保留公開後設資料和官方原始連結。

最近同步: 2026年7月11日

當前來源:腫瘤會議訊號 · 主題:全部主題 · 17 條 · 每頁 10 條

AACR: News release / Program
AACRNews release / Program
2026年4月30日來源:AACR Annual Meeting News訊號:News release

Fourth Plenary Session explored generational trends and possible drivers of early-onset cancers - AACR Annual Meeting News

Andrew T. Chan, MD, MPH, chaired the session, which examined the rising incidence of early-onset cancers and the potential contributions of obesity, bacterial exposures, and weaning to this trend. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.

檢視官方來源
AACR: News release / Program
AACRNews release / Program
2026年4月30日來源:AACR Annual Meeting News訊號:News release

Second New Drugs on the Horizon session featured first disclosure of four more innovative therapeutics - AACR Annual Meeting News

The session spotlighted a human-sialidase-armed antitumor antibody, a novel CDK2 inhibitor, a molecular glue degrader, and a dual-payload antibody-drug conjugate. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.

檢視官方來源
AACR: Program signal / Clinical Trial
AACRProgram signal / Clinical Trial
2026年4月22日來源:AACR Annual Meeting News訊號:Program signal

Third Clinical Trials Plenary Session delved into next-generation cellular therapies and immunotherapies - AACR Annual Meeting Ne...

Omar Nadeem, MD, discussed results of the CAR-PRISM trial, which evaluated the use of ciltacabtagene autoleucel in patients with high-risk smoldering myeloma, an early, asymptomatic form of multiple myeloma. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.

檢視官方來源
AACR: Official news release / Immunotherapy
AACROfficial news release / Immunotherapy
2026年4月21日來源:AACR News Releases訊號:Official news release

Early Myocarditis Onset After Immunotherapy May Predict Treatment-related Fatality

Co-occurrence of myocarditis with myositis and myasthenia gravis may also increase risk of death. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.

檢視官方來源
AACR: Official news release
AACROfficial news release
2026年4月21日來源:AACR News Releases訊號:Official news release

Exposure to Wildfire Smoke May Be Linked To Increased Risk of Developing Several Cancers

Exposure to wildfire smoke was associated with a significantly increased risk of lung, colorectal, breast, bladder, and blood cancer. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.

檢視官方來源
AACR: Official news release
AACROfficial news release
2026年4月21日來源:AACR News Releases訊號:Official news release

Intralesional Nivolumab May Be Effective Against Precancerous Oral Lesions

The treatment preserved quality of life. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.

檢視官方來源
AACR: Conference signal
AACRConference signal
2026年4月20日來源:AACR News Releases訊號:Conference signal

American Association for Cancer Research Inaugurates New Leadership During AACR Annual Meeting 2026

Keith T. Flaherty, MD, FAACR, has begun his term as AACR President. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.

檢視官方來源